ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

DUPIXENT
Asthma/COPD
Miscellaneous dermatological conditions
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

DUPIXENT Rx

Generic Name and Formulations:
Dupilumab 200mg/1.14mL, 300mg/2mL; soln for SC inj; preservative-free.

Company:
Sanofi US and Regeneron

Therapeutic Use:

Indications for DUPIXENT:

As an add-on maintenance treatment in patients with moderate-to-severe asthma with an eosinophilic phenotype or with oral corticosteroid dependent asthma.

Limitations Of use:

Not for relief of acute bronchospasm or status asthmaticus.

Adult:

Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. Initially 400mg (two 200mg inj at different sites) followed by 200mg every other week; or, initially 600mg (two 300mg inj at different sites) followed by 300mg every other week. For those with oral corticosteroids-dependent asthma or with co-morbid moderate-to-severe atopic dermatitis for which Dupixent is indicated: initially 600mg followed by 300mg every other week.

Children:

<12yrs: not established.

Warnings/Precautions:

Discontinue if significant hypersensitivity reaction occurs; treat appropriately. Advise patients to report new onset or worsening eye symptoms. Avoid abrupt discontinuation of any corticosteroids upon Dupixent initiation. Atopic dermatitis patients with co-morbid asthma. Pre-existing helminth infections; treat prior to Dupixent initiation. Do not inject into tender, damaged, bruised or scarred skin. Pregnancy. Nursing mothers.

Pharmacological Class:

Interleukin-4 receptor alpha antagonist.

Interactions:

Avoid concomitant live vaccines. Concomitant CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider dose adjustment.

Adverse Reactions:

Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye; hypersensitivity. Also asthma: oropharyngeal pain, eosinophilia.

Generic Availability:

NO

How Supplied:

Single-dose prefilled syringes—2 (with needle shield)

Indications for DUPIXENT:

Moderate-to-severe atopic dermatitis in adults who are not adequately controlled with topical prescription therapies or when they are not advisable.

Adult:

Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. ≥18yrs: Initially 600mg (two 300mg inj at different sites) followed by 300mg every other week. May use with or without topical corticosteroids. Topical calcineurin inhibitors may also be used, but should be reserved only for problem areas (eg, face, neck, intertriginous and genital areas).

Children:

<18yrs: not established.

Warnings/Precautions:

Discontinue if significant hypersensitivity reaction occurs; treat appropriately. Advise patients to report new onset or worsening eye symptoms. Avoid abrupt discontinuation of any corticosteroids upon Dupixent initiation. Atopic dermatitis patients with co-morbid asthma. Pre-existing helminth infections; treat prior to Dupixent initiation. Do not inject into tender, damaged, bruised or scarred skin. Pregnancy. Nursing mothers.

Pharmacological Class:

Interleukin-4 receptor alpha antagonist.

Interactions:

Avoid concomitant live vaccines. Concomitant CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider dose adjustment.

Adverse Reactions:

Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye; hypersensitivity. Also asthma: oropharyngeal pain, eosinophilia.

Generic Availability:

NO

How Supplied:

Single-dose prefilled syringes—2 (with needle shield)

Sign Up for Free e-Newsletters